GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment.
Ageing Res Rev
; 93: 102134, 2024 Jan.
Article
em En
| MEDLINE
| ID: mdl-38008402
ABSTRACT
According to the facts and figures 2023stated that 6.7 million Americans over the age of 65 have Alzheimer's disease (AD). The scenario of AD has reached up to the maximum, of 4.1 million individuals, 2/3rd are female patients, and approximately 1 in 9 adults over the age of 65 have dementia with AD dementia. The fact that there are now no viable treatments for AD indicates that the underlying disease mechanisms are not fully understood. The progressive neurodegenerative disease, AD is characterized by amyloid plaques and neurofibrillary tangles (NFTs) of abnormally hyperphosphorylated tau protein and senile plaques (SPs), which are brought on by the buildup of amyloid beta (Aß). Numerous attempts have been made to produce compounds that interfere with these characteristics because of significant research efforts into the primary pathogenic hallmark of this disorder. Here, we summarize several research that highlights interesting therapy strategies and the neuroprotective effects of GLP-1, Sigma, and, AGE-RAGE receptors in pre-clinical and clinical AD models.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Neurodegenerativas
/
Doença de Alzheimer
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Ageing Res Rev
Assunto da revista:
GERIATRIA
Ano de publicação:
2024
Tipo de documento:
Article